Biovitrum AB has decided to discontinue early research into small molecule drugs in order to refocus its resources on the development of biologicals. This follows the company’s acquisition in September 2008 of global sales rights for two biologics from Amgen Inc and the signing of an exclusive licensing agreement for a third.
